ArticleJournal of inflammation research2026
An Evolutionary Research Framework for the Tumor Microenvironment in Gastric Cancer.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The tumor microenvironment (TME) plays a central role in the pathogenesis, progression, and therapeutic resistance of gastric cancer (GC). Despite a rapidly expanding body of research, this field lacks a systematic conceptual framework to integrate fragmented knowledge. This study aims to construct an evolutionary framework capable of interpreting the developmental dynamics and future directions of research on the TME in GC, thereby revealing the process of its core paradigm shifts. Methods: We conducted a systematic synthesis of the knowledge domain regarding the TME in GC and constructed a comprehensive analytical framework to trace the evolution of dominant research themes and identify associated paradigm shifts. Results: We propose a "two-phase evolutionary framework." Our analysis indicates that the field has transitioned from a basic mechanism exploration phase to the current translational integration phase. Early research focused on deconstructing fundamental inflammatory components, such as stromal fibroblasts and regulatory T cells, and their functions in processes like tumor growth and migration. The current paradigm has shifted decisively toward clinical translation centered on immunotherapy. This phase is characterized by concerted efforts to employ machine learning for quantifying immune infiltration, to develop prognostic models and biomarkers, and to deeply explore mechanisms of immune evasion as well as the unique TME of specific subtypes including gastroesophageal junction cancer. Conclusion: This study develops an evolutionary framework for the TME in GC, charting its shift from basic research to clinical targeting. We propose that future work should focus on three connected areas: developing multi-omics integration platforms for microenvironment analysis to drive more precise prognostic and predictive models; second, exploring therapies targeting inflammatory pathways to overcome immunotherapy resistance, intensifying research on subtype-specific TME to enable personalized therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.